or Try an Advanced Search...

    Metastatic Castration Resistant Prostate Cancer Stocks List

    Symbol Grade Name % Change
    CRDF D Cardiff Oncology, Inc. -0.59
    EXEL B Exelixis, Inc. 0.35
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research
    Related Stock Lists: Cancer Prostate Cancer Resistant Prostate Cancer Acute Myeloid Leukemia Adenosine Advanced Solid Tumors Antineoplastic Drugs Biotechnology Cancer Treatment Chemotherapy Clinical Medicine Colorectal Cancer Cyclopropanes Daiichi Sankyo Drugs Leukemia Lymphoma Medicine Metastatic Colorectal Cancer Nektar Therapeutics

    Related ETFs - A few ETFs which own one or more of the above listed Metastatic Castration Resistant Prostate Cancer stocks.

    Symbol Grade Name Weight
    IDNA D iShares Genomics Immunology and Healthcare ETF 6.44
    FBT D First Trust Amex Biotech Index Fund 4.51
    PBE D PowerShares Dynamic Biotech & Genome 3.86
    CANC D Tema Oncology ETF 2.93
    BRNY A Burney U.S. Factor Rotation ETF 2.63
    View all Metastatic Castration Resistant Prostate Cancer ETFs...
    Compare ETFs
    Compare IDNA to BRNY Compare IDNA to CANC Compare PBE to CANC

        Metastatic Castration Resistant Prostate Cancer Stocks Recent News

        Date Stock Title
        Nov 20 EXEL Zacks.com featured highlights Amazon, Maplebear, Exelixis and Doximity
        Nov 19 CRDF Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
        Related Industries: Biotechnology Diagnostics & Research
        Related Stock Lists: Cancer Prostate Cancer Resistant Prostate Cancer Acute Myeloid Leukemia Adenosine Advanced Solid Tumors Antineoplastic Drugs Biotechnology Cancer Treatment Chemotherapy Clinical Medicine Colorectal Cancer Cyclopropanes Daiichi Sankyo Drugs Leukemia Lymphoma Medicine Metastatic Colorectal Cancer Nektar Therapeutics
        Metastatic Castration Resistant Prostate Cancer

        Metastatic Castration Resistant Prostate Cancer (mCRPC) is an advanced form of prostate cancer that has spread to other parts of the body and is resistant to hormone therapy. It is a very aggressive form of cancer that is difficult to treat and has a poor prognosis. Treatment options for mCRPC include chemotherapy, immunotherapy, and targeted therapies.

        Browse All Tags